{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:03Z","timestamp":1779951723544,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16097-w","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:33:27Z","timestamp":1777426407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Qiquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"16097_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40779-022-00406-y","volume":"9","author":"YH Jin","year":"2022","unstructured":"Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9:44\u20139. https:\/\/doi.org\/10.1186\/s40779-022-00406-y.","journal-title":"Mil Med Res"},{"key":"16097_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2016.12.011","volume":"316","author":"SE Farr","year":"2017","unstructured":"Farr SE, Chess-Williams R, McDermott CM, Gemcitabine. Selective cytotoxicity, induction of inflammation and effects on urothelial function. Toxicol Appl Pharmacol. 2017;316:1\u20139. https:\/\/doi.org\/10.1016\/j.taap.2016.12.011.","journal-title":"Toxicol Appl Pharmacol"},{"key":"16097_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bju.70060","volume":"137","author":"AC Rhodes","year":"2026","unstructured":"Rhodes AC, McClintic KA, Witt E, Nwosu I, Balk KR, Reis C, et al. Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. BJU Int. 2026;137:360\u20137. https:\/\/doi.org\/10.1111\/bju.70060.","journal-title":"BJU Int"},{"key":"16097_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.urolonc.2011.03.011","volume":"31","author":"P Gontero","year":"2013","unstructured":"Gontero P, Fiorito C, Oderda M, Pappagallo G, Brausi M. Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? Urol Oncol. 2013;31:671\u20135. https:\/\/doi.org\/10.1016\/j.urolonc.2011.03.011.","journal-title":"Urol Oncol"},{"key":"16097_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ajur.2020.03.003","volume":"8","author":"MG Sagara Ruwan Kumara","year":"2021","unstructured":"Sagara Ruwan Kumara MG, Thiranagama P, Sosai C, Abeygunasekera A. A case of follicular cystitis treated successfully with diethylcarbamazine. Asian J Urol. 2021;8:235\u20137. https:\/\/doi.org\/10.1016\/j.ajur.2020.03.003.","journal-title":"Asian J Urol"},{"key":"16097_CR6","doi-asserted-by":"publisher","first-page":"110776","DOI":"10.1016\/j.ijscr.2024.110776","volume":"126","author":"EA Hamza","year":"2025","unstructured":"Hamza EA, Reda T, Salim O, Hachem ES, Yassine N. Follicular cystitis, a rare diagnosis in an emergency setting: a case report and literature review. Int J Surg Case Rep. 2025;126:110776\u201381. https:\/\/doi.org\/10.1016\/j.ijscr.2024.110776.","journal-title":"Int J Surg Case Rep"},{"key":"16097_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/dc.24267","volume":"47","author":"P Rohra","year":"2019","unstructured":"Rohra P, Yan L, Mir F, Farrell MR, Gattuso P, Cheng L. Follicular cystitis in urine cytology: a clinical and cytopathologic study. Diagn Cytopathol. 2019;47:1223\u20138. https:\/\/doi.org\/10.1002\/dc.24267.","journal-title":"Diagn Cytopathol"},{"key":"16097_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","volume":"28","author":"BN Breyer","year":"2010","unstructured":"Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010;28:510\u20134. https:\/\/doi.org\/10.1016\/j.urolonc.2008.11.019.","journal-title":"Urol Oncol"},{"key":"16097_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.urolonc.2025.10.022","volume":"44","author":"K Arulraj","year":"2026","unstructured":"Arulraj K, Aggarwal N, Nayak B. Single dose perioperative intravesical instillation of gemcitabine versus mitomycin-C following resection of non-muscle invasive bladder cancer: a randomized controlled trial. Urol Oncol. 2026;44:e7\u201313. https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.022.","journal-title":"Urol Oncol"},{"key":"16097_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"key":"16097_CR11","doi-asserted-by":"publisher","first-page":"102699","DOI":"10.1016\/j.fjurol.2024.102699","volume":"34","author":"C Abou Chaaya","year":"2024","unstructured":"Abou Chaaya C, Ourfali S, Marchand C, Merienne C, Ruffion A, Brouzes H, et al. Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC. Fr J Urol. 2024;34:102699\u2013706. https:\/\/doi.org\/10.1016\/j.fjurol.2024.102699.","journal-title":"Fr J Urol"},{"key":"16097_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28:543\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.20.8199.","journal-title":"J Clin Oncol"},{"key":"16097_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12894-020-00610-9","volume":"20","author":"R Li","year":"2020","unstructured":"Li R, Li Y, Song J, Gao K, Chen K, Yang X, et al. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. BMC Urol. 2020;20:97\u2013104. https:\/\/doi.org\/10.1186\/s12894-020-00610-9.","journal-title":"BMC Urol"},{"key":"16097_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14740338.2024.2393283","volume":"24","author":"X Liu","year":"2025","unstructured":"Liu X, Wang Z, Peng C, Zhou J, Chen M, Luo L, et al. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system. Expert Opin Drug Saf. 2025;24:1095\u2013102. https:\/\/doi.org\/10.1080\/14740338.2024.2393283.","journal-title":"Expert Opin Drug Saf"},{"key":"16097_CR15","first-page":"493","volume":"38","author":"S Peng","year":"2016","unstructured":"Peng S, Haixiao W, Han W, Yang H. Clinical analysis of 16 cases of follicular cystitis. Med Zhejiang. 2016;38:493\u20134.","journal-title":"Med Zhejiang"},{"key":"16097_CR16","first-page":"1780","volume":"155","author":"PJ Cozzi","year":"1996","unstructured":"Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. J Urol. 1996;155:1780\u20134.","journal-title":"J Urol"},{"key":"16097_CR17","doi-asserted-by":"publisher","first-page":"115057","DOI":"10.1016\/j.intimp.2025.115057","volume":"162","author":"W Xiong","year":"2025","unstructured":"Xiong W, Liu Y, Yang H, Zhang B, Zhang X, Du Y, et al. Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. Int Immunopharmacol. 2025;162:115057\u201362. https:\/\/doi.org\/10.1016\/j.intimp.2025.115057.","journal-title":"Int Immunopharmacol"},{"key":"16097_CR18","first-page":"11547","volume":"30","author":"KR Wang","year":"2023","unstructured":"Wang KR, Simhal RK, Dinatale GG, Li L, Chandrasekar T. Recurring cystitis cystica and cystitis glandularis masquerading as urothelial carcinoma. Can J Urol. 2023;30:11547\u201351.","journal-title":"Can J Urol"},{"key":"16097_CR19","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.1038\/s41598-022-12528-3","volume":"12","author":"S Tsukahara","year":"2022","unstructured":"Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, et al. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. Sci Rep. 2022;12:8535\u201343. https:\/\/doi.org\/10.1038\/s41598-022-12528-3.","journal-title":"Sci Rep"},{"key":"16097_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.bjc.6603242","volume":"95","author":"V Mey","year":"2006","unstructured":"Mey V, Giovannetti E, Braud FD, Nannizzi S, Curigliano G, Verweij F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer. 2006;95:289\u201397. https:\/\/doi.org\/10.1038\/sj.bjc.6603242.","journal-title":"Br J Cancer"},{"key":"16097_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/FPC.0b013e32834e9eba","volume":"22","author":"K Kiyotani","year":"2012","unstructured":"Kiyotani K, Uno S, Mushiroda T, Takahashi A, Kubo M, Mitsuhata N, et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmaco Geno. 2012;22:229\u201335. https:\/\/doi.org\/10.1097\/FPC.0b013e32834e9eba.","journal-title":"Pharmaco Geno"},{"key":"16097_CR22","doi-asserted-by":"publisher","first-page":"23330","DOI":"10.1038\/s41598-025-06705-3","volume":"15","author":"MI Shoulkamy","year":"2025","unstructured":"Shoulkamy MI, Mohammed TO, Ide H, Nakano T. DNA-protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses. Sci Rep. 2025;15:23330\u20137. https:\/\/doi.org\/10.1038\/s41598-025-06705-3.","journal-title":"Sci Rep"},{"key":"16097_CR23","doi-asserted-by":"publisher","unstructured":"Bargonetti J, Champeil E, Tomasz M. Differential toxicity of DNA adducts of mitomycin C. J Nucleic Acids. 2010;698960\u20136. https:\/\/doi.org\/10.4061\/2010\/698960.","DOI":"10.4061\/2010\/698960"},{"key":"16097_CR24","doi-asserted-by":"publisher","first-page":"114676","DOI":"10.1016\/j.isci.2026.114676","volume":"29","author":"P Rollin","year":"2026","unstructured":"Rollin P, Pluskwa B, Artru E, Le Vaslot T, Kartasheva-Ebertz D, Biron D, et al. BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4\u2009+\u2009Th1 responses. iScience. 2026;29:114676. https:\/\/doi.org\/10.1016\/j.isci.2026.114676.","journal-title":"iScience"},{"key":"16097_CR25","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3390\/biomedicines11113062","volume":"11","author":"Y Takeda","year":"2023","unstructured":"Takeda Y, Kato T, Sabrina S, Naito S, Ito H, Emi N, Matsumoto K, Suzuki K. Intracellular Major Histocompatibility Complex Class II and C-X-C Motif Chemokine Ligand 10-Expressing Neutrophils Indicate the State of Anti-Tumor Activity Induced by Bacillus Calmette-Gu\u00e9rin. Biomedicines. 2023;11:3062\u20137.","journal-title":"Biomedicines"},{"key":"16097_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Rev Urol. 2014;11:153\u201362.","journal-title":"Nat Rev Urol"},{"key":"16097_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.urolonc.2007.11.031","volume":"26","author":"MP Simons","year":"2008","unstructured":"Simons MP, O\u2019Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol. 2008;26:341\u20135.","journal-title":"Urol Oncol"},{"key":"16097_CR28","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1080\/03007995.2024.2411424","volume":"40","author":"TI Totev","year":"2024","unstructured":"Totev TI. Overall burden and impact on health-related quality of life associated with intravesical treatment of patients with non-muscle invasive bladder cancer in the United States. Curr Med Res Opin. 2024;40:2003\u201311. https:\/\/doi.org\/10.1080\/03007995.2024.2411424.","journal-title":"Curr Med Res Opin"},{"key":"16097_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41687-025-00864-7","volume":"9","author":"C Rutherford","year":"2025","unstructured":"Rutherford C, Tait MA, Costa DSJ, et al. Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI. J Patient Rep Outcomes. 2025;9:36\u201342. https:\/\/doi.org\/10.1186\/s41687-025-00864-7.","journal-title":"J Patient Rep Outcomes"},{"key":"16097_CR30","doi-asserted-by":"publisher","first-page":"9189","DOI":"10.1097\/MS9.0000000000004251","volume":"87","author":"J Taj","year":"2025","unstructured":"Taj J, Ikkurthy N, Ekouo J. Reappraising intravesical gemcitabine in BCG-unresponsive nonmuscle-invasive bladder cancer: lessons from contemporary re-analysis. Ann Med Surg. 2025;87:9189\u201390.","journal-title":"Ann Med Surg"},{"key":"16097_CR31","unstructured":"The clinical effectiveness. and safety of intravesical mitomycin-C and gemcitabine sequential therapy (IMGeS). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06388720. Accessed 1 Mar 2026."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16097-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:10:23Z","timestamp":1779948623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16097-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16097"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16097-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as a sub-analysis of a larger retrospective study approved by the Clinical Research Ethics Committee of Ningbo Integrated Traditional Chinese and Western Medicine Hospital (Approval No.: 2026-014, dated March 11, 2026). The original study was entitled \u201cThe relationship between recurrence of bladder cancer beyond one year after surgery and dietary knowledge, attitudes, and long-term dietary patterns: a retrospective case-control study based on the coastal area of Zhejiang Province.\u201d The present case series was derived from patients within that approved cohort. All procedures were performed in accordance with the 1964 Declaration of Helsinki, and written informed consent was obtained from all participants. Written informed consent was obtained from all patients for the publication of this case series and any images (including cystoscopic and histopathological figures). A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"680"}}